Skip to content

Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders

Validity of the World Health Organization CIDI 5.0 for Assessing Lifetime Prevalence of Mental Disorders: A Clinical Reappraisal Study Using the SCID-5

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07604753
Enrollment
300
Registered
2026-05-22
Start date
2025-05-14
Completion date
2028-01-01
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Posttraumatic Stress Disorder (PTSD)

Keywords

CIDI, Lifetime prevalence, Mental disorders, Clinical validation

Brief summary

The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders. Earlier versions, such as the CIDI 3.0, demonstrated acceptable individual-level concordance with clinical assessments based on DSM-IV criteria (Haro et al. 2006). The latest iteration (CIDI 5.0) has been updated to operationalize DSM-5 criteria. Recent evidence from a large-scale, community-based national study in Qatar suggests that under DSM-5 criteria (Khaled et al. 2024), after recalibration, the CIDI 5.0 maintains high specificity (91.9% for MDD, 94.7% for GAD, and 85.5% for PTSD). Sensitivity suggested CIDI diagnoses aligned closely with clinical "gold standard" diagnoses (51.5% for MDD, 50.7% for GAD, and 77.3% for PTSD). Despite the evidence from Qatar, there remains a lack of evidence regarding the validity of the CIDI 5.0 in population-based studies. Therefore, this study aims to evaluate the diagnostic validity of the CIDI 5.0 for Lifetime MDD, GAD, and PTSD, using the Structured Clinical Interview for DSM-5 (SCID-5) as the definitive clinical gold standard.

Interventions

DIAGNOSTIC_TESTCIDI-5

The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). Trained interviewers will administer selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes. To validate the diagnoses in the CIDI-5 group, investigators will conduct clinical re-interviews of 3 selected CIDI-5 diagnoses: major depressive disorder (MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) using the Structured Clinician Interview for DSM-5 (SCID) by a trained mental health professional with previous experience using SCID.

Sponsors

The University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All household members aged 18 years old and over are randomly sampled from the Census and Statistics Department List of Quarters * Live in the address sampled from the Census and Statistics Department List of Quarters * Reside in Hong Kong for at least six months in the past year * Able to read and communicate in Chinese or English * Without linguistic or cognitive difficulties

Exclusion criteria

* Domestic workers

Design outcomes

Primary

MeasureTime frameDescription
DepressionImmediately following intervention or recruitmentThe main outcome in this module is the lifetime prevalence of Major Depressive Disorder (MDD)
Worry and AnxietyImmediately following intervention or recruitmentThe main outcome in this module is the lifetime prevalence of Generalized Anxiety Disorder (GAD)
Stressful ExperiencesImmediately following intervention or recruitmentThe main outcome in this module is the lifetime prevalence of PTSD.

Countries

Hong Kong

Contacts

CONTACTYoona Kim, PhD
yoonak@hku.hk+852 3917 9109

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026